期刊文献+

初发2型糖尿病患者血清RAAS特性的初步分析 被引量:1

下载PDF
导出
摘要 收集初发2型糖尿病患者63例,对其进行空腹血糖(FBG)、空腹胰岛素、血脂、HbA1c、ALD、AngII等生化指标测定,并将其分别分为高血压组21例和非高血压组42例,高糖化血红蛋白(H-HbA1c)组33例和非高糖化血红蛋白(NonH-HbA1c)组30例,老年组35例和非老年组28例,分别进行相关检测指标的分析。结果通过Pearson相关性分析发现ALD、AngII与HbA1c呈显著正相关,并且AngII还与FBG呈显著正相关;ALD、AngII与患者年龄呈显著负相关;高血压组与非高血压组的ALD、AngII未见统计学差异;H-HbA1c组的FBG、HOMA-IR、ALD、AngII均分别高于Non-H-HbA1c组,差异具有统计学意义;老年组的FBG、LDL-C、ALD、AngII均分别低于非老年组,有统计学意义;多元逐步回归后,AngII与HbA1c仍具有显著正相关,ALD与年龄呈显著负向关系。结论2DM患者血循环中的ALD、AngII与2型糖尿病的糖代谢紊乱存在密切关系,并且ALD、AngII还受年龄的影响,干预肾素-血管紧张素-醛固酮系统有助于2DM的治疗。
出处 《实用糖尿病杂志》 2013年第5期37-39,共3页 Journal of Practical Diabetology
  • 相关文献

参考文献18

  • 1Banks WA, Willoughby LM, Thomas DR, et al. Insulin resist- ance syndrome in the elderly : assessment of functional, biochemical, metabolic, and inflammatory status. Diabetes Care 2007 ; 30 ( 9 ) :2369 - 2373.
  • 2Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes in- hibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002;51(6) :1699 -1707.
  • 3Thatcher S, Yiannikouris F, Gupte M, et al. The adipose renin- angiotensin system:role in cardiovascular disease. Mol Cell Endocrinol 2009 ;302(2) :111 -7.
  • 4Zhou MS, Schulman IH. Prevention of diabetes in hyperten- sive patients: results and implications from the VALUE trial. Vasc Health Risk Manag 2009 ;5 ( 1 ) :361 - 368.
  • 5Shao J, Iwashita N, Ikeda F, et al. Beneficial effects of cande- sartan,an angiotensin II type 1 receptor blocker, on beta-ceU function and morphology in db/db mice. Biochem Biophys Res Commun 2006;344(4) :1224 - 1233.
  • 6Huang Z, Jansson L, Sjnholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glu- cose tolerance in female rats. Clin Sci (Lond) 2007 ; 112 ( 1 ) : 69 - 76.
  • 7刘锐,代文杰,周毅,宋春芳,邢军.血管紧张素Ⅱ对胰岛凋亡及Fas/Fas-L表达影响的实验研究[J].哈尔滨医科大学学报,2008,42(5):468-471. 被引量:1
  • 8Kraus D, Jager J, Meier B, et al. Aldosterone inhibits uncoup- ling protein-1 ,induces insulin resistance, and stimulates proinflammato- ry adipokines in adipocytes. Horm Metab Res 2005 ; 37 ( 7 ) .. 455 - 459.
  • 9Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new- onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of hypertension 2002 ; 20 ( 9 ) : 1879 - 1886.
  • 10Julius S, Kjeldsen SE ,Weber M, et al. Outcomes in hyperten- sive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 2004 ;363 (9426) :2022 - 2031.

二级参考文献51

共引文献12

同被引文献11

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部